Background: When phenytoin is prescribed for administration via nasogastric tube, immediate-release OR) phenytoin tablets are crushed before use and extended-release (ER) phenytoin capsules are opened and only the granules are used. However, it is unknown whether the same dose of these 2 different formulations will result in the same steady-state serum phenytoin concentration.
INTRODUCTION
Epilepsy is one of the most common serious central nervous system disorders, affecting 50 million people worldwide. 1 It may cause persistent deformity (eg, neuronal destruction, brain damage, cognitive decline), decrease quality of life, and necessitate expensive treatment. In Thailand, the prevalence of epilepsy is 29.2/1000 persons and the prevalence of active epilepsy is 5.9/1000 persons. 2 Although there is increasing interest in the use of new antiepileptic drugs (AEDs) (eg, lamotrigine, gabapentin, topiramate, and vigabatrin) for the management of seizure disorders in adult and elderly patients, the majority of these patients are still treated with traditional AEDs (eg, phenobarbital, carbamazepine, valproic acid, and phenytoin). In Thailand, phenytoin is a commonly used AED for adults and elderly patients because it is effective for most common seizure types. 2 Phenytoin is inexpensive, causes minimal sedation, can be given once daily, and is available in oral and parenteral formulations. 3 Although phenytoin is available in many formulations, extended-release (ER) phenytoin capsules have become popular because they are associated with good compliance. ER phenytoin capsules are available in all hospitals of Thailand, while immediate-release (IR) phenytoin tablets are only available in some hospitals. Therefore, patients who are prescribed phenytoin while they are receiving enteral tube feeding might be administered either IR phenytoin tablets or ER phenytoin capsules through the nasogastric tube. Because the whole tablet or capsule cannot be fed directly through the nasogastric tube, the tablet must be crushed or the capsules need to be opened so that only the granules are used.
In 1982, Bauer 4 reported low serum concentrations of phenytoin in 20 neurosurgical patients receiving 300 mg of phenytoin suspension via nasogastric tube while they were receiving continuous nasogastric tube feedings. When the feedings were discontinued, the average phenytoin concentration increased from 2.59 1Jg/mL to 10.22 1Jg/mL within 7 days. Subsequently, several studies 5-8 supported this interaction, while others 9-u did not. The exact mechanism of interaction is unknown. Some studies suggested that a physical incompatibility between phenytoin and certain components of enteral feeding formulas (eg, protein hydrolysate) resulted in binding of phenytoin particles and a subsequent decrease in bioavailability. 12-14 One study 15 suggested that binding of phenytoin to the tube lumen was the mechanism underlying this effect, while others 14,16,17 proposed that the interaction was pH-related.
There is no indication for using either phenytoin tablets or phenytoin capsules in patients receiving enteral tube feeding; however, when phenytoin is prescribed for these patients, it is a common practice to dispense the IR tablet form, because crushing an IR dosage form is generally not prohibited as a method of administration. Where the tablet is not available, ER phenytoin capsules are used. Because ER dosage forms are generally not modified, the question emerges as to whether discarding the capsule and using only the granules will affect the bioavailability and, in turn, the clinical outcome. Phenytoin plasma concentration of 10 to 20 mg/L is generally accepted as therapeutic. Plasma concentrations in the range of 5 to 10 mg/L can be therapeutic for some patients, but concentrations <5 mg/L are not likely to be effective.
The aim of this study was to determine whether ER phenytoin capsules (using only the granules) can be used interchangeably with IR phenytoin tablets (which have been crushed) by comparing steady-state serum phenytoin concentrations after administration through an enteral feeding tube.
PATIENTS AND METHODS Patients
This was an open-label, crossover clinical trial comparing steady-state serum phenytoin concentration (Css) after administration of phenytoin acid IR 50-mg tablets* and phenytoin sodium ER 100-mg capsulest (equivalent to 92 mg of phenytoin acid) through a nasogastric tube. Participants were patients at Prasat Neurological Institute (Bangkok, Thailand). The study design was approved by the Human Research Committee of Prasat Neurological Institute. Written informed consent was obtained from the patient or his/her legal guardian prior to entering the study. The study was conducted in accordance with the principles of the Declaration of Helsinki 18 and the Guideline for Good Clinical Practice. 19 Patients aged >18 years who were to receive nutrition via a nasogastric feeding tube and who were prescribed 300 mg of phenytoin monotherapy as a maintenance dose for posttraumatic seizure control were eligible for the study. Patients were excluded from the study if they were allergic to phenytoin, their dose of phenytoin had to be changed, another antiepileptic drug had to be added, any drug that might affect phenytoin pharmacokinetics had to be added, the nasogastric feeding tube was removed, or if they were discharged from the hospital or died before completion of the study.
Study Design
The study was started with the administration of phenytoin tablets, 300 mg/d (two 50-mg tablets every 8 hours). The tablets were crushed, mixed into -200 mL of blenderized diet (Prasat Neurological Institute formula composed of pork liver, pumpkin, banana or papaya, egg, sugar, vegetable oil, and water), and administered via the nasogastric tube (Curity ®, Kendall-Gammatron Inc., Nakhonpathom, Thailand), followed by -50 mL of water. The same dosage form, administration time, and administration process were continued for >5 days to ensure steady-state conditions. One blood sample was then obtained from the vein at the forearm <1 hour before the morning dose, and the serum phenytoin concentration was determined.
The dosage formulation was then changed to phenytoin capsules in all patients, 300 mg/d (three 100-mg capsules once daily). There was no washout period. The capsules were opened and the contents were mixed into -200 mL of blenderized diet and administered via the nasogastric tube, followed by -50 mL of water. This process was again continued for >5 days, when 1 blood sample was collected from the forearm <1 hour before the morning dose, and the serum phenytoin concentration was determined.
The incidences of seizures and minor and serious adverse events (AEs) were observed and recorded.
Blood Sample Collection
For each patient, a 5-mL blood sample was drawn from the vein at the forearm <1 hour before the administration of the morning dose of phenytoin on day 5 to obtain the Cmh ~. The sample was centrifuged at 5000 rpm for 5 minutes, and the serum was separated. Immediate assay was preferred; if the assay could not be completed within 8 hours, the serum was stored at 2°C to 8°C until the assay could be completed, which was usually within 24 hours.
The phenytoin concentration in serum samples was determined using a turbid metric inhibition immunoassay method with an automated analyzer (Synchron CX ® Systems, Beckman Coulter Inc., Fullerton, California).
Statistical Analysis
Since the sample size is small, <20, the test statistic Z cannot always be assumed to be normally distributed. Both a parametric method (comparison of the means using paired t tests) and a nonparametric method (Wilcoxon signedrank test under the null hypothesis that the median difference is equal to 0) were performed by SPSS version 11.5 software (SPSS Inc., Chicago, Illinois).
Sample Size Estimation
Sample size was estimated according to the formula2°:
where S was defined as standard deviation, Z~ and Z6 were defined as the values that cut off the areas of c¢ and 13 in the upper and lower tails of the standard normal distribution, and D was defined as the difference needed to detect a significant change in clinical outcomes (set to >1 1Jg/mL for the purpose of this study).
Bauer 4 reported the mean (SD) serum phenytoin concentration in 10 neurosurgical patients to be 2.59 (0.96) 1Jg/mL when a phenytoin suspension of 300 mg/d was concomitantly administered with continuous nasogastric feeding. Another 10 neurosurgical patients in that study receiving phenytoin suspension without concurrent nasogastric tube feeding had a mean (SD) serum phenytoin concentration of 2.72 (1.09) 1Jg/mL (the SDs from Bauer's study were used to estimate the sample size because the characteristics of the patients and the dosage of phenytoin used were similar to those of the present study), the S 2 was calculated as follows: Because the SDs of the Cs~ from tablet and capsule dosage forms were expected to be higher than those of the suspension dosage form used by Bauer, the sample size required was doubled and was determined to be >17 patients.
Pharmacokinetic Parameter Calculation
Phenytoin is -90% bound to serum albumin, and it is the pharmacologically active unbound drug that is in equilibrium with the receptor site. Therefore, to correct for patients who have hypoalbuminemia (serum albumin concentration lower than the normal value of 4.4 g/dL), the normal binding serum phenytoin concentration (eND) should be calculated using the following equation21: CNB = Cobs/0.9(Alb/4.4 ) + 0.1, where COb s is the measured serum phenytoin concentration and Alb is the serum albumin concentration.
The rate of phenytoin metabolism approaches its maximum at therapeutic concentrations and thus is described as capacity-limited, which results in clearance values that decrease with increasing plasma concentrations. The maximum metabolic rate of phenytoin (Vmax) can be calculated from the formula that is derived from the Michaelis-Menten equation 21 as follows:
Vmax/F = (S)(dose/~)(K m + C~)/C~s, where K,,,, the Michaelis-Menten constant, is the substrate concentration at which the rate of metabolism is half of Vma x (here, assumed to be 4 mg/L [population average]), F is the phenytoin bioavailability of the study dosage form, and Cs~ = CNB in this study.
RESULTS
Inpatient charts at the neurosurgical wards of Prasat Neurological Institute were screened from October 2004 to October 2005. Thirty-three patients who met the inclusion criteria were recruited. Four patients refused to enroll in the study and, after the initiation of the study, 3 patients discontinued the nasogastric feeding tube because they could take food by mouth, 4 patients were discharged from the hospital due to clinical improvement, 3 patients died, and 2 patients were excluded because the dosage of phenytoin had to be changed from 300 mg/d, leaving 17 patients to complete the study ( Baseline patient demographic characteristics and laboratory findings are provided in Table I . Three (17.6%) patients had a history of smoking and 5 (29.4%) had a history of alcohol abuse, although all of them had stopped smoking and consuming alcohol before entering the study. Of the patients who completed the study, 14 (82.4%) were admitted for cerebrovascular disease, 2 (11.8%) had a brain tumor, and 1 (5.9%) had a head injury. Some patients had concomitant diseases, such as hypertension (9 [ 
Serum Phenytoin Concentration
After _>5 days of treatment with phenytoin tablets, 300 mg/d to ensure steadystate condition, mean (SD) serum phenytoin Css was 6.03 (5.92) 1Jg/mL (median, 4.60 1Jg/mL; range, 1.2-26.6 1Jg/mL). Mean (SD) serum albumin concentration was 2.51 (0.49) g/dL (median, 2.40 g/dL; range, 1.8-3.7 g/dL). Nearly all serum albumin concentrations (except for one) were lower than the normal range (3.5-5.0 gm/dL). Serum phenytoin CNB was 10.33 (11.60) 1Jg/mL (median, 6.99 1Jg/mL; range, 2.10-52.25 1Jg/mL) (Table II) . After >5 days of treatment with phenytoin capsules, 300 mg/d, mean (SD) serum phenytoin Css was 3.80 (2.70) pg/mL (median, 3.00 pg/mL; range, 0.4-9.1 pg/mL). Serum albumin concentration was 2.45 (0.40) g/dL (median, 2.60 g/dL; range, 1.8-3.2 g/dL). Serum phenytoin CNB was 6.28 (4.76) pg/mL, (median, 4.75 IJg/mL; range, 0.85-17.86 IJg/mL) ( Table II) .
As shown in Table III , tablet and capsule Cs~ and CNB were significantly different at c¢ = 0.05 (2-sided) based on nonparametric method (P = 0.019 and 0.035, Wilcoxon signed rank test). However, tablet and capsule C~ and CNB were not significantly different at c¢ = 0.05 (2-sided) based on parametric method (P = 0.054 and 0.075, paired t test). Because of 1 patient with outlier values, the mean differences were again determined with parametric method without the data of that patient for both C~s (P = 0.028) and CNB (e = 0.051). 
Clinical Outcomes
None of the patients showed signs of seizures or minor or serious AEs associated with phenytoin use during the study period and none were reported by any patient.
Michaelis-Menten Parameters
Vmax/F (where F is a bioavailability factor; the percentage or fraction of the administered dose that reaches the systemic circulation) of each patient, assuming K m = 4 mg/L, is shown in Table IV (Table V) .
DISCUSSION
Serum phenytoin concentrations varied greatly among the patients after treatment with phenytoin tablets and also after treatment with phenytoin capsules via nasogastric tube. Phenytoin tablets and capsules require different methods of preparation. In our study, the tablets were crushed and suspended in a blenderized diet before administration. Granule size depended on which investigator crushed the tablets, possibly resulting in variation in phenytoin bioavailability. Phenytoin capsules are more convenient to use, because they do not required crushing before administration. However, the granules were smaller and more bulky (lighter and higher in volume). Some granules stuck to the feeding tube and required additional water to flush them down, which also might have resulted in variation in bioavailability.
All patients enrolled received a blenderized diet (Prasat Neurological Institute formula) through a nasogastric tube. Other studies, 12,15 which used commercial enteral feeding formulas, reported that the hydrolyzed protein or isolated protein in these formulas caused a decrease in serum phenytoin concentration. Previous studies found that coadministration of the drug with food caused the serum phenytoin concentration to be lower than with interrupted feeding, in which feeding was stopped for 2 hours before and 2 hours after phenytoin was administered. 4,5 In our study, many patients administered with phenytoin tablets or capsules via nasogastric tube had serum phenytoin concentrations that were lower than the proposed therapeutic range (10-20 pg/mL in general, 5-20 pg/mL in some patients). This might have been caused by the interaction of phenytoin with the enteral feeding formula (which contains intact protein) when the drug was coadministered with the diet. The main reason the serum phenytoin concentration obtained with capsules was significantly lower than that obtained with tablets might have been due to the difference in salt forms between the 2 dosing forms. The tablets contained phenytoin in free acid form, while the capsules contained phenytoin in sodium salt form. When a salt form of a drug is administered, the fraction of the total molecular weight that is the active moiety should be considered. 21 For phenytoin sodium, 92% of the administered dose is active drug. Thus 300 mg of phenytoin sodium has 276 mg of phenytoin and 24 mg of sodium. Because metabolism of phenytoin is capacity-limited, resulting in nonlinear pharmacokinetics, a small increase in the dosage could result in a disproportionately high increase in serum drug concentration. The dosage used in this study was 300 mg/d of either the free acid form or the sodium salt form of phenytoin, with the salt form containing less phenytoin than the free acid form. Vma×/F of the tablets and capsules were not significantly different at the 95% CI (Table V) .
Because Vma × is the pharmacokinetic parameter that is normally assumed to be constant in individual patients, this may suggest that the difference in bioavailabilities (when the differences in dosages caused by differences in the salt forms is accounted for) between the tablet and the capsule caused by the process of administration (crushing the tablet vs opening the capsule) or the dosage forms (IR tablet vs ER capsule) were not important. The number of patients who completed the study was small and there was great variability among patients even when they were administered the same dosage form.
Two methods of statistical analysis were used in this study; paired t tests and the Wilcoxon signed-rank test. Because the sample size was small and there was a patient with outlier values, the data might not have been normally distributed, indicating that the Wilcoxon signed-rank test might be preferred.
Limitations
Due to the small cohort observed (17 patients), the actual therapeutic effects of the drug might not have been observed, as all of the patients recruited were neurosurgical patients who were prescribed phenytoin prophylaxis for posttraumatic seizures. This study was performed and observed in a clinical setting, making it difficult to control for confounding factors, (eg, conditions of admission, abnormal or unstable liver conditions or albumin levels).
CONCLUSION
The steady state serum phenytoin concentration was significantly lower with ER phenytoin capsules 300 mg/d than IR phenytoin tablets 300 mg/d via nasogastric feeding tube coadministered with a blenderized diet.
